Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Acute bronchospasm 2-4 mg 3 or 4 times/day, up to 8 mg 3 or 4 times/day. As modified-release tab: 8 mg bid. IV Severe bronchospasm As 50 mcg/mL soln: 250 mcg (4 mcg/kg) injected slowly. May be repeated if necessary. As 10 mcg/mL soln: Usual rate of 3-20 mcg/min (0.3-2 mL/min). Higher doses may be used in resp failure. Uncomplicated premature labour at 22-37 wk of gestation Initial: 10 mcg/min, increasing gradually at 10-min intervals until there is response, then increase rate slowly until contractions cease. Maintain rate for 1 hr after contractions have stopped, then gradually reduce rate by 50% at intervals of 6 hr. Usual: 10-45 mcg/min. Max duration: 48 hr. IM/SC Severe bronchospasm 500 mcg (8 mcg/kg) and repeated 4 hrly as required. Inhalation Acute bronchospasm As metered-dose aerosol or dry powd inhaler: 1 or 2 inhalations up to 4 times/day. Max: 800 mcg/day. Prophylaxis of exercise-induced bronchospasm As metered-dose aerosol or dry powd inhaler: 2 inhalations 10-15 min prior to exercise. Severe bronchospasm Via nebuliser: 2.5-5 mg, up to 4 times/day or, continuously at a rate of 1-2 mg/hr. Acute severe asthma As metered-dose inhaler via spacer device: Initial: 4 inhalations, then a further 2 inhalations every 2 min according to response. Max: 10 inhalations.
IV (in the treatment of premature labour): Pre-existing or risk factors for ischaemic heart disease, gestational age <22 wk, conditions in which prolongation of pregnancy is hazardous (e.g. severe toxaemia, intrauterine infection, vag bleeding resulting from placenta praevia, eclampsia or severe preeclampsia, placental abruption, cord compression; use in threatened abortion.
Special Precautions
Hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation, HTN, DM, glaucoma, hypokalaemia, seizure disorder. Renal impairment. Elderly. Pregnancy and lactation. Monitoring Parameters Monitor BP, heart rate, electrolyte and fluid balance; glucose, lactate and K levels.
Adverse Reactions
Tremor, nervousness, nausea and vomiting, tachycardia, palpitations, chest pain, shakiness, dizziness, headache, insomnia, inhalation site sensation, hyperactivity, HTN, hypotension, increased sweating, allergic reactions, DM, muscle cramps, flu-like syndrome, conjunctivitis, UTI, hypokalaemia,. Rarely, erythema multiforme, Stevens-Johnson syndrome.
Potentially Fatal: Paradoxical bronchospasm.
Drug Interactions
Increased risk of hypokalaemia w/ K depleting agents (e.g. corticosteroid, diuretics, xanthines, digoxin). Increased uterine inertia w/ halogenated anaesth (IV). Increased risk of pulmonary oedema w/ corticosteroids. May antagonise the effect of anti-diabetics. Effects may be altered by guanethidine, reserpine, methyldopa, TCAs and MAOIs. Increased risk of CV effects w/ other sympathomimetic agents. Antagonistic effect w/ β-blockers.
ATC Classification
R03AC02 - salbutamol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03CC02 - salbutamol ; Belongs to the class of adrenergics for systemic use, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by CIMS based on salbutamol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in